A carregar...
The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
BACKGROUND: The efficacy and safety of once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i) omarigliptin as monotherapy or add on to other antihyperglycemic agents (AHAs) in patients with type 2 diabetes mellitus (T2DM) is unclear. METHODS: PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov w...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6112932/ https://ncbi.nlm.nih.gov/pubmed/30142816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011946 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|